WebApr 27, 2024 · Dicerna Pharmaceuticals’ board of directors last year doubled CEO Douglas Fambrough’s paycheck for the second time as the biotech continued its deal-making spree. Fambrough earned ... WebCEO: Douglas M. Fambrough. Employees: 78. 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA 02140 617 621 8097. www.dicerna.com ... DICERNA PHARMACEUTICALS INC DRNA: 2024-12-28 12:45:03 UTC-0.2091: 0.2891: 250000: Current Active Short Positions. Holder Issuer Net Short Position Position Date Origin;
Did you know?
WebFeb 28, 2024 · Dicerna Pharmaceuticals, Inc. (DRNA) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Lauren Stival – Stern Investor Relations, Inc. WebHumbled to be a part of this enriching discussion with some of the most amazing women of NN! ̈ #iwd2024 #diversityequityinclusion #novonordisk…
WebApr 4, 2024 · Aradhye, who is returning to Novartis, was most recently Executive Vice President and Chief Medical Officer at Dicerna Pharmaceuticals where he led the development of multiple clinical stage RNAi assets. ... CEO Novartis. “I would like to congratulate Marie-France, Shreeram, Steffen and Victor on their new roles, and extend … WebMay 28, 2024 · It would be hard to discount the role that CEO Douglas Fambrough has played in delivering the impressive results at Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) recently. Coming up to the next AGM ...
WebAug 9, 2024 · Dicerna Pharmaceuticals, Inc. (DRNA) Q2 2024 Earnings Conference Call August 9, 2024 8:00 AM ETCompany ParticipantsDoug Fambrough – Chief Executive … WebFounded: 2007. Type: Company - Public (DRNA) Industry: Biotech & Pharmaceuticals. Revenue: Unknown / Non-Applicable. Competitors: Unknown. Dicerna is working to improve the lives of people suffering from diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
WebNov 18, 2024 · About Dicerna. Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing …
WebJun 24, 2024 · The estimated Net Worth of Douglas Fambrough is at least $17.7 Million dollars as of 15 December 2024. Douglas Fambrough owns over 13,750 units of Dicerna Pharmaceuticals Inc stock worth over $9,049,693 and over the last 9 years he sold DRNA stock worth over $3,614,546. In addition, he makes $5,048,130 as President, Chief … rickshaw\u0027s bdWebJan 17, 2024 · Alnylam, the biggest of the three, was up 62%, while Dicerna's stock more than doubled and Arrowhead shares skyrocketed 422% in 2024. As Alnylam's CEO told BioPharma Dive last November, "RNAi has got its sexy back." Such heady returns are unlikely to be replicable, Arrowhead CEO Christopher Anzalone conceded in an interview … rickshaw\u0027s b3WebOther. $8,451. Total Compensation. $2,547,018. CEO Pay Ratio. For its 2024 fiscal year, DICERNA PHARMACEUTICALS INC, listed the following CEO pay ratio data on its … rickshaw\u0027s bcWebSep 22, 2024 · About Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing … rickshaw\u0027s baWebOther. $8,451. Total Compensation. $2,547,018. CEO Pay Ratio. For its 2024 fiscal year, DICERNA PHARMACEUTICALS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC. CEO Name. CEO Pay. rickshaw\u0027s bfWebMay 28, 2024 · Our data indicates that Dicerna Pharmaceuticals, Inc. has a market capitalization of US$2.4b, and total annual CEO compensation was reported as US$6.6m for the year to December 2024. Notably, that ... rickshaw\u0027s c0WebNov 18, 2024 · Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform. Bagsværd, Denmark, 18 November 2024 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna).The acquisition of Dicerna’s ribonucleic acid interference … rickshaw\u0027s bm